PT - JOURNAL ARTICLE AU - Li, Baisheng AU - Deng, Aiping AU - Li, Kuibiao AU - Hu, Yao AU - Li, Zhencui AU - Xiong, Qianling AU - Liu, Zhe AU - Guo, Qianfang AU - Zou, Lirong AU - Zhang, Huan AU - Zhang, Meng AU - Ouyang, Fangzhu AU - Su, Juan AU - Su, Wenzhe AU - Xu, Jing AU - Lin, Huifang AU - Sun, Jing AU - Peng, Jinju AU - Jiang, Huiming AU - Zhou, Pingping AU - Hu, Ting AU - Luo, Min AU - Zhang, Yingtao AU - Zheng, Huanying AU - Xiao, Jianpeng AU - Liu, Tao AU - Che, Rongfei AU - Zeng, Hanri AU - Zheng, Zhonghua AU - Huang, Yushi AU - Yu, Jianxiang AU - Yi, Lina AU - Wu, Jie AU - Chen, Jingdiao AU - Zhong, Haojie AU - Deng, Xiaoling AU - Kang, Min AU - Pybus, Oliver G. AU - Hall, Matthew AU - Lythgoe, Katrina A. AU - Li, Yan AU - Yuan, Jun AU - He, Jianfeng AU - Lu, Jing TI - Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant AID - 10.1101/2021.07.07.21260122 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.07.21260122 4099 - http://medrxiv.org/content/early/2021/07/23/2021.07.07.21260122.short 4100 - http://medrxiv.org/content/early/2021/07/23/2021.07.07.21260122.full AB - We report the first local transmission of the SARS-CoV-2 Delta variant in mainland China. All 167 infections could be traced back to the first index case. Daily sequential PCR testing of the quarantined subjects indicated that the viral loads of Delta infections, when they first become PCR+, were on average ∼1000 times greater compared to A/B lineage infections during initial epidemic wave in China in early 2020, suggesting potentially faster viral replication and greater infectiousness of Delta during early infection. We performed high-quality sequencing on samples from 126 individuals. Reliable epidemiological data meant that, for 111 transmission events, the donor and recipient cases were known. The estimated transmission bottleneck size was 1-3 virions with most minor intra-host single nucleotide variants (iSNVs) failing to transmit to the recipients. However, transmission heterogeneity of SARS-CoV-2 was also observed. The transmission of minor iSNVs resulted in at least 4 of the 30 substitutions identified in the outbreak, highlighting the contribution of intra-host variants to population level viral diversity during rapid spread. Disease control activities, such as the frequency of population testing, quarantine during pre-symptomatic infection, and level of virus genomic surveillance should be adjusted in order to account for the increasing prevalence of the Delta variant worldwide.Competing Interest StatementThe views expressed in this article are those of the authors and not necessarily those of the Guangdong Provincial Center for Diseases Control and Prevention, or the Guangdong Provincial Institute of Public Health.Funding Statement1.Science and Technology Planning Project of Guangdong (2018B020207006) 2.The Key Research and Development Program of Guangdong Province (2019B111103001) 3.Guangdong Workstation for Emerging infectious Disease Control and Prevention, Chinese Academy of Medical Sciences (2020-PT330-004)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional ethics committee of the Guangdong Provincial Center for Disease Control and Prevention (GDCDC). Written consent was obtained from patients or their guardian(s) when samples were collected. Patients were informed about the surveillance before providing written consent, and data directly related to disease control were collected and anonymized for analysis. For immunity evaluation, serum samples were collected from vaccinated volunteers in GDCDC with written consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequencing reads after primer trimming and mapped to the reference sequence (the sequences of the first index case, XG5137_GZ_2021/5/21) have been submitted to the National Genomics Data Center (https://bigd.big.ac.cn/) with submission number CRA004571. The generated consensus sequences were submitted with accession number GWHBDIM01000000-GWHBDNH01000000.